Clinical trials: Hematopoietic and Stem Cell Transplant
Acute Myeloid Leukemia, Myelodysplastic Syndrome
DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial
This phase I trial tests the safety, side effects and best dose of decoy-resistant interleukin-18 (DR-18) and how well it works in treating patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
- Trial name
- NCT06492707
- Testing
- Decoy-resistant interleukin-18, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Leukemia, Myelodysplastic Syndrome
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant
- Trial name
- NCT07573111
- Testing
- QUAIL-100
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Laguna Biotherapeutics, Inc.
B-cell Lymphoma, Non-Hodgkin's Lymphoma
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant
Patients with B-cell lymphoma who relapse after autologous transplant tend to have a poor prognosis. Currently, there is no standard treatment for such patients.
- Trial name
- NCT00434629
- Testing
- Bexxar
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pennsylvania
Graft Versus Host Disease, GVHD
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
This study will test PANO in combination with tacrolimus/sirolimus (TAC/SIR) for acute GVHD prevention. The purpose of this study is to determine if Panobinostat (PANO) when used in combination with sirolimus and tacrolimus will…
- Trial name
- NCT02588339
- Testing
- Panobinostat, Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cutaneous T Cell Lymphoma (CTCL), Brentuximab Vedotin
Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance
Allogeneic hematopoietic stem cell transplantation (alloHSCT) showed efficacy in advanced-stage, high-risk, treatment sensitive cutaneous T-cell lymphomas (CTCL) in a prospective, propensity score-matched controlled study…
- Trial name
- BeCALM (NCT07178457)
- Testing
- Brentuximab Vedotin (Bv)
- Volunteers
- 84 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation
Virtual Reality Intervention for Symptom Management in Stem Cell Transplantation
The goal of this clinical trial is to evaluate whether a virtual reality (VR) intervention based on the Symptom Management Model can reduce physical and psychosocial symptoms during hematopoietic stem cell transplantation (HSCT)…
- Conditions
- Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Nursing Interventions, Symptom Management
- Trial name
- NCT07145359
- Testing
- Virtual Reality Intervention
- Volunteers
- 30 people
- Sponsor
- Halic University
Multiple Sclerosis
High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis
Multiple Sclerosis is a disease that may be caused by the immune system reacting against the nervous system. It is possible, that by changing the immune system we can modify the progression of this disease.
- Trial name
- NCT00040482
- Testing
- Cyclophosphamide, ATG, MESNA
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor College of Medicine
Hematopoietic Neoplasms, Hematopoietic Malignancy
Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation
The main purpose of this study is to determine if a novel peer support intervention (STEPP) is feasible among patients undergoing hematopoietic stem cell transplantation (HSCT).
- Trial name
- STEPP (NCT06010017)
- Testing
- STEPP Intervention
- Where
- 2 sites in United States
- Volunteers
- 136 people
- Sponsor
- Brigham and Women's Hospital
Antibacterial Prophylaxis, Hematological Malignancies
Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematologic malignancies.
- Conditions
- Antibacterial Prophylaxis, Hematological Malignancies, Allogenetic Hematopoietic Stem Cell Transplantation, Imipenem
- Trial name
- NCT03733340
- Testing
- Imipenem
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies
- Trial name
- NCT02231710
- Testing
- BPX-501 and Rimiducid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Haematological Malignancy
Impact of Oral Nutritional Supplements on Patients Undergoing Haematopoietic Stem Cell Transplantation
Malnutrition is common after haematopoietic stem cell transplantation (HSCT), and is a well-known prognostic factor for survival.
- Trial name
- NCT05460013
- Testing
- Traditional Control, Oral Nutritional Supplement
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
AML (Acute Myelogenous Leukemia)
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
This is a single-center, prospective, single-arm, exploratory clinical study. To explore the efficacy and safety of avapritinib in patients with recurrent acute myeloid leukemia after allogeneic hematopoietic stem cell…
- Trial name
- NCT06783790
- Testing
- Avapritinib, azacitidine, Venetoclax
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Graft-versus-Host Disease, Stomatitis
Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis
This study was designed to be conducted in 2 parts. The first part is a pilot study to test the effects of topical thalidomide gel 20mg applied to up to 3 oral ulcers in patients who have developed oral chronic…
- Trial name
- NCT00075023
- Testing
- Thalidomide Gel
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Nursing Research (NINR)
Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
This phase 2 trial studies how well cluster of differentiation 8 (CD8)+ memory T-cells work as a consolidative therapy following a donor non-myeloablative hematopoietic cell transplant in treating patients with leukemia or…
- Conditions
- Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma
- Trial name
- NCT02424968
- Testing
- Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Robert Lowsky
Critical Illness, Ventilated Patients
Critical Illness After Hematopoietic Cell Transplantation
This is a prospective, multicenter observational trial for patients who develop critical illness after hematopoietic cell transplantation.
- Conditions
- Critical Illness, Ventilated Patients, Hematopoetic Stem Cell Transplantation, Transplant Complication
- Trial name
- CARE-HCT (NCT07328724)
- Where
- 6 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Peking University People's Hospital
Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD
This study is to assess the efficacy of Neihulizumab versus "conventional therapy" and to evaluate safety, pharmacokinetics and immunogenicity in treating steroid-refractory acute Graft-vs-Host Disease
- Trial name
- NCT02694770
- Testing
- Neihulizumab Treatment, Conventional Treatment
- Where
- 2 sites in United States
- Sponsor
- AbGenomics B.V Taiwan Branch
Distress, Hematopoietic Stem Cell Transplantation
Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant
This study will examine the effectiveness of problem-solving education for patients who are undergoing a stem cell transplant and their caregivers.
- Trial name
- NCT00766883
- Testing
- Problem Solving Education
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Multiple Myeloma and Plasma Cell Neoplasm
Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00941720
- Testing
- busulfan, cyclophosphamide, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Leukemia, Myelodysplastic Syndromes
Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI
Graft-versus-host disease (GVHD) is an important complication after transplantation, with an incidence of 40-60%, which can increase non-relapse mortality if poorly controlled.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia (SAA)
- Trial name
- NCT07796620
- Testing
- Sirolimus, Ruxolitinib, MMF
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Myelodysplastic Syndromes, Myeloid Leukemia, Acute
TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Single-arm, single-center phase II trial to evaluate the antileukemic activity and safety/tolerability of TMLI/cyclophosphamide and etoposide conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in…
- Trial name
- TMLI-MA (NCT06598969)
- Testing
- Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.